- Home
- NSSC vs PRAX Comparison
NSSC vs PRAX Comparison
Compare NSSC & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSSC
- PRAX
- Stock Information
- Founded
- NSSC 1969
- PRAX 2015
- Country
- NSSC United States
- PRAX United States
- Employees
- NSSC N/A
- PRAX N/A
- Industry
- NSSC Telecommunications Equipment
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- NSSC Telecommunications
- PRAX Health Care
- Exchange
- NSSC Nasdaq
- PRAX Nasdaq
- Market Cap
- NSSC 899.1M
- PRAX 599.7M
- IPO Year
- NSSC N/A
- PRAX 2020
- Fundamental
- Price
- NSSC $30.14
- PRAX $47.26
- Analyst Decision
- NSSC Strong Buy
- PRAX Strong Buy
- Analyst Count
- NSSC 5
- PRAX 10
- Target Price
- NSSC $33.60
- PRAX $99.20
- AVG Volume (30 Days)
- NSSC 301.2K
- PRAX 297.8K
- Earning Date
- NSSC 08-25-2025
- PRAX 08-12-2025
- Dividend Yield
- NSSC 1.86%
- PRAX N/A
- EPS Growth
- NSSC N/A
- PRAX N/A
- EPS
- NSSC 1.22
- PRAX N/A
- Revenue
- NSSC $181,227,000.00
- PRAX $8,122,000.00
- Revenue This Year
- NSSC N/A
- PRAX N/A
- Revenue Next Year
- NSSC $6.02
- PRAX $6,358.50
- P/E Ratio
- NSSC $24.69
- PRAX N/A
- Revenue Growth
- NSSC N/A
- PRAX 270.02
- 52 Week Low
- NSSC $19.00
- PRAX $26.70
- 52 Week High
- NSSC $58.09
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- NSSC 69.16
- PRAX 66.10
- Support Level
- NSSC $26.44
- PRAX $40.93
- Resistance Level
- NSSC $30.23
- PRAX $44.40
- Average True Range (ATR)
- NSSC 0.87
- PRAX 2.24
- MACD
- NSSC 0.09
- PRAX 0.11
- Stochastic Oscillator
- NSSC 95.84
- PRAX 89.64
About NSSC NAPCO Security Technologies Inc.
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.